<DOC>
	<DOCNO>NCT01511497</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics , pharmacodynamics PF-04427429 healthy woman .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Generally healthy woman , nonchild bear potential , age 18 65 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test . Body Mass Index ( BMI ) 17.5 35.0 kg/m2 ; total body weight 50 kg ( 110 lb ) 120 kg ( 265 lb ) inclusive . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , hepatic , psychiatric , neurologic , disease . Subjects asymptomatic , seasonal allergy time dose exclude . Women childbearing potential . History diagnosis ocular disease condition would confound assessment ocular safety , diabetic retinopathy , uveitis , severe wet dry AMD .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>PF-04427429</keyword>
</DOC>